Patent ID: 6316652
Filing Date: 2001-11-13
Classification: A61K

Abstract:
An enantiopure targeted agent, comprising:a targetor having the structure ##STR61##wherein L is O, S or NR.sup.10, and wherein each R' independently is hydrogen or an unsaturated or saturated branched or unbranched aliphatic or alicyclic group having from 1 to 6 carbon atoms, and optionally at least one hetero atom, wherein R.sup.10 is hydrogen or an unsaturated or saturated branched or unbranched aliphatic or alicyclic group having from 1 to 6 carbon atoms and optionally at least one hetero atom, wherein each of R.sup.3 independently is hydrogen or unsaturated or saturated branched or unbranched aliphatic or alicyclic group having from one to 50 carbon atoms, and optionally at least one hetero atom, or R.sup.8 and R.sup.9 in combination is ##STR62##wherein each of W, X and Y independently is (CR.sup.12).sub.p, O, S or N, wherein each R.sup.11 independently is a lone pair of electrons, NR.sup.12 R.sup.13, OR.sup.12, SR.sup.12 or a hydrogen or an unsaturated or saturated branched or unbranched aliphatic or alicyclic group having from 1 to 50 carbon atoms, and optionally at least one hetero atom, wherein p is an integer of from 0 to 2, wherein each R.sup.12 and R.sup.13 independently is hydrogen or an unsaturated or saturated branched or unbranched aliphatic or alicyclic group having from 1 to 50 carbon atoms; and a metal containing pharmaceutical agent covalently bonded to the targetor.